Table 3 Relation between clinicopathological data and hypermethylation of the PRTFDC1 CpG island

From: PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation

  n PRTFDC1 hypermethylation (%)a Pb
Total 47 8 (17.0)  
Gender
 Male 19 2 (10.5) 0.4448
 Female 28 6 (21.4)  
Age
 Median (range) years 69.0 (49–90)   
 >60 12 1 (8.3) 0.6593
60 35 7 (20.0)  
Smoking c
 Smoker 13 0 (0) 0.1317
 Nonsmoker 21 5 (23.8)  
Alcohol d
 Drinker 10 0 (0) 0.1472
 Nondrinker 21 5 (23.8)  
Differentiation e
 Well-mod 34 6 (17.6) >0.9999
 Poor 4 1 (25.0)  
TNM classification
T stage    
 T1 3 0 (0) >0.9999
 T2-4 44 8 (18.2)  
N stage
 N0 32 4 (12.5) 0.2455
 N1-3 15 4 (26.7)  
M stage
 M0 40 7 (17.5) >0.9999
 M1 7 1 (14.3)  
Stage
 I, II 16 3 (18.8) 0.6645
 III, IV 31 5 (16.1)  
  1. aMethylation status was determined by methylation-specific PCR as described in Materials and methods.
  2. bP-values are from the χ2 or Fisher exact test and were statistically significant when <0.05 (two-sided).
  3. cNo information in 13 cases.
  4. dNo information in 16 cases.
  5. eNo information in nine cases.